This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Longs Shareholders Cinch CVS Caremark Deal

OKLAHOMA CITY -- CVS Caremark (CVS - Get Report) has proven again it knows how to close a deal with its successful bid for Longs Drug Stores (LDG).

By overcoming threats of a bidding war, CVS has managed to win control of Longs without raising its original $2.9 billion bid for the company. By Monday morning, CVS had convinced Longs investors to sell 76.5% of their shares at the company's original $71.50 offering price. CVS needed to secure just two-thirds of Longs' stock to seal the deal.

Longs' stock, up 2 cents to $71.47 Monday, reflected the finality of the situation.

"We are very pleased with the strong response to our tender offer," CVS CEO Tom Ryan said on Monday. "Having now satisfied all closing conditions, we look forward to promptly purchasing the tendered shares and completing our merger with Longs."

Last month, before the market cratered, CVS faced an uphill battle for the company. Longs shareholders, convinced that their company was worth far more, originally shunned CVS's offer and tendered only a fraction of their shares. Meanwhile, rival Walgreen (WAG) stepped forward with a $75-per-share bid.

This month, however, Walgreen had a change of heart. Faced with a plunging stock market, the company decided to keep its $3 billion and let Longs sell itself to CVS instead. To some, the move made sense.

"With the stock market revaluation we're witnessing even as we write this, we doubt this will be the last takeover bid launched in headier days that is withdrawn," Gimme credit analyst Carl Levenson wrote on Oct. 9. "CVS might also want to reconsider the premium it is paying for Longs and the value of its real estate, but it's probably gone too far to turn back now."
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CVS $92.25 0.75%
RAD $7.88 2.20%
AAPL $118.88 0.96%
FB $105.74 -1.13%
GOOG $748.28 -1.02%


Chart of I:DJI
DOW 17,812.19 +19.51 0.11%
S&P 500 2,089.14 +2.55 0.12%
NASDAQ 5,102.8080 +0.33 0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs